Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

J&J Duragesic Pediatric Exclusivity Keeps Mylan Fentanyl Patch Off The Market Until January

This article was originally published in The Pink Sheet Daily

Executive Summary

FDA rejects Mylan's argument linking pediatric exclusivity with the 30-month stay. Mylan says it will sue FDA to restore final approval of its ANDA, which is now deemed tentatively approved.

You may also be interested in...



Mylan Cautions Investors Over Sell-Side Analysts' Estimates

Following a surge in trading volume due to Carl Icahn's clearance to purchase up to 11.9% of Mylan stock, the company says that analysts' estimates may not reflect negative changes in the generic industry. Mylan plans to provide guidance "as soon as practically possible."

Mylan Cautions Investors Over Sell-Side Analysts' Estimates

Following a surge in trading volume due to Carl Icahn's clearance to purchase up to 11.9% of Mylan stock, the company says that analysts' estimates may not reflect negative changes in the generic industry. Mylan plans to provide guidance "as soon as practically possible."

Mylan’s Duragesic Generic Cannot Escape J&J’s Pediatric Exclusivity – Court

D.C. federal judge upholds FDA’s determination that the generic fentanyl patch cannot come to market until after pediatric exclusivity expires in January.

Related Content

Topics

UsernamePublicRestriction

Register

PS059782

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel